BCRX
BIOCRYST PHARMACEUTICALS INC
Next earnings Aug 3, 2026 (before open) · consensus $0.14 EPS, $189M rev
Last earnings -2.2% on 2026-05-06
$9.94
▲ +0.40%$9.94▼ -1.58%
over 1Y
L $6.24EODHDH $10.10
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.4%
1W+8.8%
1M+9.0%
3M+6.5%
YTD+32.5%
1Y-1.6%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Buy
Revenue grew 94.1% YoY.
The read
Quality fundamentals and an attractive price line up (~363% below fair value) — the rarer case where both the business and the entry look good.
BIOCRYST PHARMACEUTICALS INC shows $875M in FY2025 revenue (+94.1% YoY), a 30.2% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $157M | $271M | $331M | $451M | $875M |
| Gross profit | — | — | — | — | — |
| Operating income | -$178M | -$148M | -$104M | -$2.54M | $341M |
| Net income | -$184M | -$247M | -$227M | -$88.9M | $264M |
| Diluted EPS | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
| Net margin | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.40B
EV / EBITDA7.0
EV / Sales2.7
EV / FCF7.0
P / FCF7.2
PEG (trailing)0.02
Earnings yield10.6%
FCF yield13.8%
Quality & risk
ROIC (est.)—
Free cash flow$345M
Total debt$0.00
Net cash$89.7M
Altman Z-Score2.64 grey
Piotroski F-Score6/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+20.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗8-KPeriod ending 2026-06-112026-06-12open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗
Frequently asked
- Is BIOCRYST PHARMACEUTICALS INC (BCRX) a buy?
- BCRX currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 94.1% YoY.
- What is BCRX's fair value?
- A Modified-Graham model based on BCRX's SEC fundamentals estimates a fair value of about $45.98. It is an estimate from reported earnings, not a price target.
- Is BCRX overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, BCRX currently appears undervalued relative to its SEC-grounded earnings power.
- What is BIOCRYST PHARMACEUTICALS INC's quality score?
- BCRX scores 78.33333333333331/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000882796, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 5:49:01 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.